ArticleCancer biology & therapy2008
Tumor cell-specific blockade of CXCR4/SDF-1 interactions in prostate cancer cells by hTERT promoter induced CXCR4 knockdown: A possible metastasis preventing and minimizing approach.
Article in Cancer biology & therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- The Role of Cytokines in the Metastasis of Solid Tumors to the Spine: Systematic Review.International journal of molecular sciences · 2023Pooled it
- The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.Drug design, development and therapy · 2015Pooled it
- Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow.PloS one · 2013Trial
- Prostate Cancer Imaging Beyond PSMA: Applications of GRPR, AR, and Amino Acid Tracers.Diagnostics (Basel, Switzerland) · 2025Review
- Tumor cells express and maintain HMGB1 in the reduced isoform to enhance CXCR4-mediated migration.Frontiers in immunology · 2024Article
- Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies.Translational oncology · 2020Article
- Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis.International journal of molecular sciences · 2020Review
- Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer.Journal of biomedical research · 2016Review
- Meta-Analysis of the Relationship between CXCR4 Expression and Metastasis in Prostate Cancer.The world journal of men's health · 2014Article
- CXCL12 Modulates Prostate Cancer Cell Adhesion by Altering the Levels or Activities of β1-Containing Integrins.International journal of cell biology · 2014Article
- CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells.Molecular cancer research : MCR · 2014Article
- Association between SDF1-3'A or CXCR4 gene polymorphisms with predisposition to and clinicopathological characteristics of prostate cancer with or without metastases.Molecular biology reports · 2012Article
- Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior.Prostate cancer and prostatic diseases · 2012Review
- [Bone metastasis in prostate cancer].Der Urologe. Ausg. A · 2012Article
- SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis.Molecular cancer · 2011Article
- Cell type specific, traceable gene silencing for functional gene analysis during vertebrate neural development.Nucleic acids research · 2011Article
- Article
- Human aging and CD31+ T-cell number, migration, apoptotic susceptibility, and telomere length.Journal of applied physiology (Bethesda, Md. : 1985) · 2010Article
- Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.Nature genetics · 2009Article
- New insights into the role of CXCR4 in prostate cancer metastasis.Cancer biology & therapy · 2008Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stromal cell-derived factor-1 (SDF-1)/CXCR4 pathway has been shown to play an important role in prostate cancer (PCa) metastasis and siRNA expression using cell-specific promoters has been demonstrated to be a potential tool for targeted gene therapy. Here, we illustrate that human telomerase reverse transcriptase (hTERT) promoter-induced CXCR4 knockdown inhibits PCa bone metastasis. We first investigated CXCR4 expressions and interactions of CXCR4/SDF-1 in PCa cells, developed a retrovirus system that could stably express CXCR4 small hairpin RNA driven by hTERT promoter and then determined the inhibitory effects of cell-specific blockade of CXCR4/SDF-1 pathway on PCa metastasis. It was shown that both PCa tissues and cell lines expressed CXCR4 and the expression in PCa tissue had a positive correlation to clinical stages while not to Gleason scores or serum PSA level. PCa metastases most presenting human tissues expressed high levels of SDF-1. Exogenous SDF-1 enhanced in vitro adhesion, migration and invasion of PCa cells and these bioeffects were repressed by hTERT promoter-induced CXCR4-shRNA expression. This CXCR4 knockdown was also found to significantly inhibit bone metastasis in vivo. We conclude that CXCR4/SDF-1 pathway plays an important role in PCa bone metastasis. hTERT promoter-induced tumor cell-specific CXCR4 gene silencing may prevent in vitro invasiveness and in vivo bone metastasis of PCa. These findings may enable new avenues of prevention and treatment for PCa metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.